Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Litoxetine HCl 是一种选择性5-羟色胺(5-HT)再摄取抑制剂(SSRI)和混合5-羟色胺拮抗剂,可用于治疗尿失禁。Litoxetine HCl 在没有抗毒蕈碱特性的浓度下(10 nM-1 microM)引起大鼠离体食道肌肉粘膜的浓度依赖性松弛,使卡巴胆碱张力降低达37%,更高浓度的Litoxetine HCl(3微摩-300微摩)与明显的松弛有关,直至取消卡巴胆碱张力。以前在离体豚鼠肠道中证明的利托西汀的抗心律失常活性,在浓度大于1 microM 时在大鼠离体食道肌肉粘膜中发挥了作用。 Litoxetine HCl 的5-HT 释放作用可以解释利托西汀对未处理的大鼠组织中的5-HT 诱导的松弛的效力,这种效力被pCPA 处理所逆转。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 693 | 现货 | ||
5 mg | ¥ 1,600 | 现货 | ||
10 mg | ¥ 2,390 | 现货 | ||
25 mg | ¥ 3,970 | 现货 | ||
50 mg | ¥ 5,780 | 现货 | ||
100 mg | ¥ 7,880 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,390 | 现货 |
产品描述 | Litoxetine HCl is a selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) and mixed 5-hydroxytryptamine antagonist used in the treatment of urinary incontinence. Litoxetine HCl in the absence of antimuscarinic concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxation of isolated oesophageal muscle mucosa in rats, reducing carbachol tone by up to 37%. Higher concentrations of Litoxetine HCl (3 microM-300 microM) were associated with significant relaxation up to abolition of carbachol tone. The antiarrhythmic activity of Litoxetine HCl, previously demonstrated in the isolated guinea pig intestine, was exerted in the isolated rat oesophageal muscle mucosa at concentrations greater than 1 microM. The 5-HT-releasing effect of Litoxetine HCl could explain the potency of Litoxetine HCl on 5-HT-induced relaxation in untreated rat tissue, which was reversed by pCPA treatment. |
靶点活性 | [3H]-DAU 6215:0.3 microM |
体外活性 | Litoxetine HCl(0.3-3微摩尔)对5-HT曲线的高效及低效阶段表现出拮抗作用。[1] 同时,Litoxetine HCl(1及3微摩尔)对5-MeOT的反应以浓度依赖的方式向右移动。[1] |
体内活性 | Litoxetine HCl(每日两次,连续4天),一种新型特异性5-羟色胺再摄取抑制剂。[2] |
别名 | litoxetine HCL(86811-09-8 Free base) |
分子量 | 277.79 |
分子式 | C16H20ClNO |
CAS No. | T67956L |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (81 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5998 mL | 17.9992 mL | 35.9984 mL | 89.996 mL |
5 mM | 0.72 mL | 3.5998 mL | 7.1997 mL | 17.9992 mL | |
10 mM | 0.36 mL | 1.7999 mL | 3.5998 mL | 8.9996 mL | |
20 mM | 0.18 mL | 0.9 mL | 1.7999 mL | 4.4998 mL | |
50 mM | 0.072 mL | 0.36 mL | 0.72 mL | 1.7999 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Litoxetine HCl T67956L GPCR/G Protein Neuroscience 5-HT Receptor litoxetine HCL(86811-09-8 Free base) Inhibitor inhibitor inhibit